S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
Log in

NASDAQ:JAGX - Jaguar Health Stock Price, Forecast & News

$0.96
+0.08 (+9.09 %)
(As of 01/21/2020 04:00 PM ET)
Today's Range
$0.89
Now: $0.96
$1.08
50-Day Range
$0.55
MA: $0.69
$0.88
52-Week Range
$0.52
Now: $0.96
$36.39
Volume3.04 million shs
Average Volume1.37 million shs
Market Capitalization$49.11 million
P/E RatioN/A
Dividend YieldN/A
Beta0.8
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:JAGX
CUSIPN/A
Phone415-371-8300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.42 million
Book Value$5.80 per share

Profitability

Net Income$-32,150,000.00
Net Margins-771.25%

Miscellaneous

Employees40
Market Cap$49.11 million
Next Earnings Date4/8/2020 (Estimated)
OptionableNot Optionable

Receive JAGX News and Ratings via Email

Sign-up to receive the latest news and ratings for JAGX and its competitors with MarketBeat's FREE daily newsletter.


Jaguar Health (NASDAQ:JAGX) Frequently Asked Questions

What is Jaguar Health's stock symbol?

Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."

How were Jaguar Health's earnings last quarter?

Jaguar Health Inc (NASDAQ:JAGX) released its quarterly earnings data on Thursday, November, 14th. The biotechnology company reported ($1.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $1.69. The biotechnology company earned $0.97 million during the quarter, compared to analyst estimates of $4.22 million. Jaguar Health had a negative net margin of 771.25% and a negative return on equity of 675.03%. View Jaguar Health's Earnings History.

When is Jaguar Health's next earnings date?

Jaguar Health is scheduled to release their next quarterly earnings announcement on Wednesday, April 8th 2020. View Earnings Estimates for Jaguar Health.

What price target have analysts set for JAGX?

2 Wall Street analysts have issued 12 month price targets for Jaguar Health's stock. Their forecasts range from $3.00 to $5.00. On average, they anticipate Jaguar Health's share price to reach $4.00 in the next year. This suggests a possible upside of 316.7% from the stock's current price. View Analyst Price Targets for Jaguar Health.

What is the consensus analysts' recommendation for Jaguar Health?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jaguar Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Jaguar Health.

Has Jaguar Health been receiving favorable news coverage?

Media coverage about JAGX stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Jaguar Health earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Jaguar Health.

Who are some of Jaguar Health's key competitors?

What other stocks do shareholders of Jaguar Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Conatus Pharmaceuticals (CNAT), Biopharmx (BPMX), Cara Therapeutics (CARA), Neovasc (NVCN), Precipio (PRPO), PTC Therapeutics (PTCT), Biocept (BIOC), Cascadian Therapeutics (CASC), Cellectar Biosciences (CLRB) and FuelCell Energy (FCEL).

Who are Jaguar Health's key executives?

Jaguar Health's management team includes the folowing people:
  • Ms. Lisa A. Conte, Founder, CEO, Pres & Director (Age 60)
  • Ms. Karen S. Wright, CFO & Treasurer (Age 63)
  • Dr. Steven R. King, Exec. VP of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec. (Age 61)
  • Dr. Pravin R. Chaturvedi, Chair of Scientific Advisory Board & Acting Chief Scientific Officer (Age 56)
  • Mr. Jonathan S. Wolin, Chief Compliance Officer & Corp. Counsel

When did Jaguar Health IPO?

(JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

How do I buy shares of Jaguar Health?

Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Jaguar Health's stock price today?

One share of JAGX stock can currently be purchased for approximately $0.96.

How big of a company is Jaguar Health?

Jaguar Health has a market capitalization of $49.11 million and generates $4.42 million in revenue each year. The biotechnology company earns $-32,150,000.00 in net income (profit) each year or ($158.74) on an earnings per share basis. Jaguar Health employs 40 workers across the globe.View Additional Information About Jaguar Health.

What is Jaguar Health's official website?

The official website for Jaguar Health is http://www.jaguaranimalhealth.com/.

How can I contact Jaguar Health?

Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at 415-371-8300.


MarketBeat Community Rating for Jaguar Health (NASDAQ JAGX)

Community Ranking:  4.4 out of 5 (star star star star)
Outperform Votes:  1,798 (Vote Outperform)
Underperform Votes:  241 (Vote Underperform)
Total Votes:  2,039
MarketBeat's community ratings are surveys of what our community members think about Jaguar Health and other stocks. Vote "Outperform" if you believe JAGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Featured Article: Closed-End Mutual Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel